ArticleJournal of urban health : bulletin of the New York Academy of Medicine2019
Beliefs Associated with Pharmacy-Based Naloxone: a Qualitative Study of Pharmacy-Based Naloxone Purchasers and People at Risk for Opioid Overdose.
Article in Journal of urban health : bulletin of the New York Academy of Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 54 citations in OpenAlex.
- Public perceptions and willingness-to-pay regarding over-the-counter (OTC) naloxone: A national cross-sectional survey informed by the Theory of Planned Behavior.Exploratory research in clinical and social pharmacy · 2026Article
- Availability of Naloxone in Retail Pharmacies Following Introduction of Over-the-Counter Status.JAMA network open · 2026Article
- Development of a Low-Barrier, Reimbursable Take-Home Naloxone Program at a Regional Health System.The western journal of emergency medicine · 2025Article
- Naloxone Acceptance among Nightclub Attendees in New York City.Journal of community health · 2025Article
- Access to Naloxone and Preferences for Its Online Purchase Among Individuals Affected by Opioid Misuse.Cureus · 2025Article
- Pharmacy Naloxone Standing Order and Community Opioid Fatality Rates Over Time.JAMA network open · 2024Article
- Naloxone Availability and Cost After Transition to an Over-the-Counter Product.JAMA health forum · 2024Article
- Neighborhood and Individual Disparities in Community-Based Naloxone Access for Opioid Overdose Prevention.Journal of urban health : bulletin of the New York Academy of Medicine · 2024Article
- Motivation to Carry Naloxone: A Qualitative Analysis of Emergency Department Patients.American journal of health promotion : AJHP · 2023Article
- Public Perceptions of Community Pharmacy-Based Naloxone Services: A National Cross-Sectional Survey.Pharmacy (Basel, Switzerland) · 2022Article
- Attitude changes following short-form opioid overdose video education: a pilot study.Harm reduction journal · 2022Article
- Patient perspectives on naloxone receipt in the emergency department: a qualitative exploration.Harm reduction journal · 2022Article
- Expert views on state-level naloxone access laws: a qualitative analysis of an online modified-Delphi process.Harm reduction journal · 2022Article
- Limited access to pharmacy-based naloxone in West Virginia: Results from a statewide purchase trial.Drug and alcohol dependence · 2022Article
- Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies.Substance abuse · 2022Article
- Gaps in naloxone ownership among people who inject drugs during the fentanyl wave of the opioid overdose epidemic in New York City, 2018.Substance abuse · 2022Article
- Effectiveness and implementability of state-level naloxone access policies: Expert consensus from an online modified-Delphi process.The International journal on drug policy · 2021Article
- A free mailed naloxone program in Philadelphia amidst the COVID-19 pandemic.The International journal on drug policy · 2021Article
- Prescribing Naloxone to High-Risk Patients in the Emergency Department: Is it Enough?Joint Commission journal on quality and patient safety · 2021Article
- Australian Community Pharmacy Harm-Minimisation Services: Scope for Service Expansion to Improve Healthcare Access.Pharmacy (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
Abstract
Drug overdose is the leading cause of unintentional death in the USA and the majority of deaths involve an opioid. Pharmacies are playing an increasingly important role in getting naloxone-the antidote to an opioid overdose-into the community. The aim of the current study was to understand, from the perspective of those who had obtained naloxone at the pharmacy, whose drug using status and pain patient status was not known until the interviews were conducted, as well as those who had not obtained naloxone at the pharmacy but were at risk for overdose, factors that impact the likelihood of obtaining pharmacy-based naloxone (PBN). Fifty-two participants from two New England states were interviewed between August 2016 and April 2017. We used a phenomenological approach to investigate participants' beliefs about pharmacy-based naloxone. The social contextual model was chosen to structure the collection and analysis of the qualitative data as it takes into account individual, interpersonal, organizational (pharmacy), community, and societal influences on a specific health behavior. Of the 52 people interviewed, 24 participants had obtained naloxone from the pharmacy in the past year, of which 4% (n = 1) self-disclosed during the interview current illicit drug use and 29% (n = 7) mentioned using prescribed opioid pain medication. Of the 28 people who had not obtained naloxone from the pharmacy, 46% (n = 13) had obtained an over the counter syringe from a pharmacy in the past month and had used an opioid in the past month, and 54% (n = 15) had used a prescribed opioid pain medication in the past month but did not report a syringe purchase. Several main themes emerged from the interview data. Individual-level themes were as follows: helplessness and fear, naloxone as empowerment to help, and past experiences at the pharmacy. Interpersonal-level themes were as follows: concern for family and friends, and sources of harm reduction information. Themes associated with pharmacy-level influence were as follows: perceived stigma from pharmacists, confusion at the pharmacy counter, and receptivity to pharmacists' offer of naloxone; community-level themes were as follows: community caretaking and need for education and training. Finally, themes at the societal-level of influence were as follows: generational crisis, and frustration at lack of response to opioid crisis. Overall our findings reveal factors at multiple levels which may play a role in likelihood of obtaining naloxone at the pharmacy. These factors can be used to inform interventions seeking to increase provision of pharmacy-based naloxone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.